https://www.nasdaq.com/press-release/ardelyx-launching-ibsrelar-second-quarter-of-2022-2021-11-30
https://www.nasdaq.com/press-release/ardelyx-reports-third-quarter-2021-financial-results-2021-11-12
https://www.nasdaq.com/press-release/ardelyx-to-present-at-the-jefferies-london-healthcare-conference-2021-11-11
https://www.nasdaq.com/press-release/ardelyx-reports-additional-positive-data-supporting-clinical-utility-of-tenapanor-at
https://www.nasdaq.com/press-release/ardelyx-to-pursue-formal-dispute-resolution-for-tenapanor-2021-11-04
https://www.nasdaq.com/press-release/ardelyx-announces-four-tenapanor-presentations-at-asns-kidney-week-2021-2021-10-29
https://www.nasdaq.com/press-release/ardelyx-provides-corporate-update-following-type-a-meeting-with-fda-2021-10-13
https://www.nasdaq.com/press-release/ardelyx-announces-publication-of-52-week-phase-3-phreedom-trial-2021-09-03
https://www.nasdaq.com/press-release/ardelyx-reports-second-quarter-2021-financial-results-2021-08-13
https://www.nasdaq.com/press-release/kessler-topaz-meltzer-check-llp-announces-a-securities-fraud-class-action-filed-0
https://www.nasdaq.com/press-release/shareholder-alert%3a-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-79
https://www.nasdaq.com/press-release/ardelyx-receives-complete-response-letter-from-u.s.-fda-for-new-drug-application-for
https://www.nasdaq.com/press-release/ardelyx-provides-regulatory-update-on-new-drug-application-for-tenapanor-for-the
https://www.nasdaq.com/press-release/ardelyx-announces-presentations-at-era-edta-virtual-congress-2021-2021-06-07
https://www.nasdaq.com/press-release/ardelyx-to-present-at-the-jefferies-2021-virtual-healthcare-conference-2021-05-25
https://www.nasdaq.com/press-release/ardelyx-reports-first-quarter-2021-financial-results-and-recent-business-highlights
https://www.nasdaq.com/press-release/ardelyx-announces-extension-of-the-pdufa-review-period-for-tenapanor-for-the-control
https://www.nasdaq.com/press-release/ardelyx-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2021-04-16
https://www.nasdaq.com/press-release/ardelyx-collaboration-partner-kyowa-kirin-announces-initiation-of-phase-3-clinical
https://www.nasdaq.com/press-release/ardelyx-announces-upcoming-data-presentation-at-isn-world-congress-of-nephrology-2021
https://www.nasdaq.com/press-release/ardelyx-announces-poster-presentations-educational-symposium-and-exhibitor-showcase
https://www.nasdaq.com/press-release/ardelyx-appoints-muna-bhanji-r.ph-to-its-board-of-directors-2021-03-15
https://www.nasdaq.com/press-release/ardelyx-reports-fourth-quarter-and-full-year-2020-financial-results-and-recent
https://www.nasdaq.com/press-release/therapeutique-knight-annonce-le-lancement-commercial-canadien-de-ibsrelamc-un-nouveau
https://www.nasdaq.com/press-release/ardelyx-to-present-at-the-10th-annual-svb-leerink-global-healthcare-conference-2021
https://www.nasdaq.com/press-release/ardelyx-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference
https://www.nasdaq.com/press-release/ardelyx-to-present-at-the-jefferies-virtual-london-healthcare-conference-2020-11-10
https://www.nasdaq.com/press-release/ardelyx-to-webcast-virtual-analyst-day-2020-11-06
https://www.nasdaq.com/press-release/ardelyx-reports-third-quarter-2020-financial-results-and-business-highlights-2020-11
https://www.nasdaq.com/press-release/ardelyx-and-kyowa-kirin-highlight-new-data-supporting-the-clinical-safety-and
https://www.nasdaq.com/press-release/ardelyx-launches-can-we-do-better-campaign-at-asns-kidney-week-2020-2020-10-22
https://www.nasdaq.com/press-release/ardelyx-announces-data-supporting-efficacy-and-safety-of-tenapanor-a-first-in-class
https://www.nasdaq.com/press-release/ardelyx-announces-fda-acceptance-for-filing-of-its-new-drug-application-of-tenapanor
https://www.nasdaq.com/press-release/ardelyx-to-participate-in-three-upcoming-investor-conferences-in-september-2020-09-08
https://www.nasdaq.com/press-release/ardelyx-reports-second-quarter-2020-financial-results-and-recent-business-highlights
https://www.nasdaq.com/press-release/ardelyx-selected-as-a-finalist-in-the-fierce-innovation-awards-for-the-development-of
https://www.nasdaq.com/press-release/ardelyx-announces-submission-of-new-drug-application-to-the-u.s.-fda-for-tenapanor
https://www.nasdaq.com/press-release/ardelyx-announces-positive-second-data-analysis-from-ongoing-normalize-phase-4-study
https://www.nasdaq.com/press-release/ardelyx-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-06-09
https://www.nasdaq.com/press-release/ardelyx-appoints-veteran-biopharma-executive-justin-renz-as-chief-financial-officer
https://www.nasdaq.com/press-release/ardelyx-to-present-at-the-jefferies-2020-virtual-healthcare-conference-2020-05-26
https://www.nasdaq.com/press-release/ardelyx-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-05-21
https://www.nasdaq.com/press-release/ardelyx-strengthens-management-team-with-appointment-of-susan-rodriguez-as-chief
https://www.nasdaq.com/press-release/ardelyx-reports-first-quarter-2020-financial-results-and-recent-business-highlights
https://www.nasdaq.com/press-release/ardelyx-appoints-onaiza-cadoret-manier-to-its-board-of-directors-2020-03-16
https://www.nasdaq.com/press-release/ardelyx-reports-fourth-quarter-and-full-year-2019-financial-results-and-recent
https://www.nasdaq.com/press-release/ardelyx-to-present-at-the-cowen-and-company-40th-annual-health-care-conference-2020
https://www.nasdaq.com/press-release/ardelyx-to-present-at-the-9th-annual-svb-leerink-global-healthcare-conference-2020-02
https://www.nasdaq.com/press-release/ardelyx-announces-pricing-of-upsized-public-offering-of-common-stock-2019-12-05
https://www.nasdaq.com/press-release/ardelyx-announces-proposed-public-offering-of-common-stock-2019-12-04
https://www.nasdaq.com/press-release/ardelyx-announces-positive-topline-results-from-pivotal-phase-3-phreedom-study
https://www.nasdaq.com/press-release/ardelyx-to-host-conference-call-on-december-3-to-review-results-from-the-pivotal
https://www.nasdaq.com/press-release/ardelyx-to-present-at-the-piper-jaffray-31st-annual-healthcare-conference-2019-11-26
https://www.nasdaq.com/press-release/ardelyx-and-kyowa-kirin-expand-partnership-with-two-additional-agreements-2019-11-25
https://www.nasdaq.com/press-release/ardelyx-announces-presentation-at-kidney-week-2019-2019-11-06
https://www.nasdaq.com/press-release/ardelyx-reports-third-quarter-2019-financial-results-and-recent-highlights-2019-11-06
https://www.nasdaq.com/press-release/ardelyx-to-host-analyst-day-in-new-york-2019-10-10
https://www.nasdaq.com/press-release/ardelyx-to-present-at-the-ladenburg-thalmann-2019-healthcare-conference-2019-09-17
https://www.nasdaq.com/press-release/ardelyx-announces-positive-results-from-the-pivotal-phase-3-amplify-study-evaluating
https://www.nasdaq.com/press-release/ardelyx-to-host-conference-call-on-september-3-to-review-results-from-the-pivotal
